Jennifer Friedman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3922261/publications.pdf

Version: 2024-02-01

933447 1058476 13 938 10 14 citations g-index h-index papers 14 14 14 2028 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Rapid whole-genome sequencing decreases infant morbidity and cost of hospitalization. Npj Genomic Medicine, 2018, 3, 10.	3.8	314
2	Intrafamilial phenotypic variability of the DYT1 dystonia: From asymptomaticTOR1A gene carrier status to dystonic storm. Movement Disorders, 2002, 17, 339-345.	3.9	142
3	TPP1 deficiency: Rare cause of isolated childhood-onset progressive ataxia. Neurology, 2015, 85, 1259-1261.	1.1	138
4	YY1 Haploinsufficiency Causes an Intellectual Disability Syndrome Featuring Transcriptional and Chromatin Dysfunction. American Journal of Human Genetics, 2017, 100, 907-925.	6.2	125
5	<i>KMT2B</i> -related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation. Brain, 2020, 143, 3242-3261.	7.6	57
6	Alternating Hemiplegia of Childhood: Retrospective Genetic Study and Genotype-Phenotype Correlations in 187 Subjects from the US AHCF Registry. PLoS ONE, 2015, 10, e0127045.	2.5	53
7	<i>Caenorhabditis elegans</i> provides an efficient drug screening platform for <i>GNAO1</i> related disorders and highlights the potential role of caffeine in controlling dyskinesia. Human Molecular Genetics, 2022, 31, 929-941.	2.9	32
8	De novo and inherited variants in ZNF292 underlie a neurodevelopmental disorder with features of autism spectrum disorder. Genetics in Medicine, 2020, 22, 538-546.	2.4	24
9	De novo variants in SNAP25 cause an early-onset developmental and epileptic encephalopathy. Genetics in Medicine, 2021, 23, 653-660.	2.4	20
10	Urine sepiapterin excretion as a new diagnostic marker for sepiapterin reductase deficiency. Molecular Genetics and Metabolism, 2015, 115, 157-160.	1.1	18
11	Novel Protein Biomarkers of Monoamine Metabolism Defects Correlate with Disease Severity. Movement Disorders, 2021, 36, 690-703.	3.9	7
12	Ending a diagnostic odyssey: Moving from exome to genome to identify cockayne syndrome. Molecular Genetics & Ending Genomic Medicine, 2021, 9, e1623.	1.2	3
13	Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome. Brain, 2022, 145, 3383-3390.	7.6	3